Russolillo Angela, Homayra Fahmida, Nosyk Bohdan
Centre for Advancing Health Outcomes, Vancouver, BC, Canada.
School of Nursing, University of British Columbia, Vancouver, BC, Canada.
Can J Psychiatry. 2025 Jun 9:7067437251347150. doi: 10.1177/07067437251347150.
ObjectiveOpioid use is a major public health issue and associated with a broad range of comorbid mental disorders. Globally, there is considerable variability in reported rates of mental disorders among individuals with opioid use disorder (OUD), limiting timely intervention and evidence-based treatment among this population. We estimate the prevalence of specific mental disorders among individuals with a concurrent OUD using population-level administrative data in British Columbia, Canada.MethodA population-based retrospective observational study using individual-level linked health administrative data in British Columbia, Canada. Individuals with an OUD and concurrent mental disorder between January 1, 2013, and August 31, 2021, were included and followed from their first indication of OUD until censoring (death, administrative loss to follow-up, or August 31, 2021). We reported annual period (2013-2021) prevalence rates and age-standardized prevalence rates per 100,000 population (stratified by sex).ResultsThe population included 73,855 individuals (female 40.6%, median age, 36 [27-48]) with an OUD and concurrent mental disorder. During the observation period anxiety disorders were the most prevalent (91.7%) mental disorders followed by depression (73.6%), bipolar disorder (35.3%), schizophrenia spectrum disorders (20.4%), and personality disorders (19.5%). Among the population, the annual period prevalence of any mental disorder increased from 35,603 in 2013 to 60,940 in 2021, with an average annual percent difference of 7.0%, driven by increases in schizophrenia spectrum disorders and attention deficit/hyperactivity disorder. Overall, the annual age-standardized prevalence of any mental disorder was higher among males.ConclusionsOur findings demonstrate a steadily growing prevalence of people with OUD and a concurrent mental disorder and emphasize the need for access to mental disorder treatment among this population. Estimating specific mental disorder prevalence is a pragmatic step toward informing clinical guidelines, service needs, and health system planning.
目的
阿片类药物的使用是一个重大的公共卫生问题,且与多种共病精神障碍相关。在全球范围内,阿片类药物使用障碍(OUD)患者中报告的精神障碍发生率存在很大差异,这限制了对该人群的及时干预和循证治疗。我们利用加拿大不列颠哥伦比亚省的人群水平行政数据,估算同时患有OUD的个体中特定精神障碍的患病率。
方法
一项基于人群的回顾性观察研究,使用加拿大不列颠哥伦比亚省个体水平的关联健康行政数据。纳入2013年1月1日至2021年8月31日期间患有OUD且并发精神障碍的个体,并从其首次出现OUD迹象开始随访,直至被审查(死亡、行政失访或2021年8月31日)。我们报告了年度(2013 - 2021年)患病率以及每10万人口的年龄标准化患病率(按性别分层)。
结果
该人群包括73,855名患有OUD且并发精神障碍的个体(女性占40.6%,中位年龄36岁[27 - 48岁])。在观察期内,焦虑症是最常见的(91.7%)精神障碍,其次是抑郁症(73.6%)、双相情感障碍(35.3%)、精神分裂症谱系障碍(20.4%)和人格障碍(19.5%)。在该人群中,任何精神障碍的年度患病率从2013年的35,603例增加到2021年的60,940例,平均年增长率为7.0%,这主要是由精神分裂症谱系障碍和注意力缺陷/多动障碍的增加所致。总体而言,男性中任何精神障碍的年度年龄标准化患病率更高。
结论
我们的研究结果表明,患有OUD且并发精神障碍的人群患病率在稳步上升,并强调了该人群获得精神障碍治疗的必要性。估算特定精神障碍的患病率是朝着为临床指南、服务需求和卫生系统规划提供信息迈出的务实一步。